Senzo Health Raises $1.8M to Develop Innovative Diagnostic Technologies
Senzo Health, a London-based life sciences company, recently announced that it has successfully raised an additional $1.8M in funding. Although the specific backers were not disclosed, this influx of capital will undoubtedly help Senzo as it seeks to further expand its operations and continue its development efforts. Spearheaded by Jeremy Stackawitz, Senzo focuses on the development of diagnostic technologies within the life sciences sector.
The primary objective of Senzo is to create a laboratory-accurate lateral flow test.
With current diagnostics often being both slow and expensive, Senzo aims to provide a solution by developing a 10-minute lateral flow test that offers the same level of accuracy as a laboratory PCR test. This innovative approach will significantly improve testing efficiency, enabling faster and more affordable diagnoses for a wide range of infections, diseases, and patients.
As an in vitro diagnostics company, Senzo is actively progressing tests for various high-need applications. These include RSV, Influenza A/B, COVID-19, STIs, Tuberculosis, Hepatitis B and C, AMR, HIV, C. difficile/Staph/MRSA, Lyme Disease, Veterinary, and Environmental/Industrial. By expanding its diagnostic capabilities across these areas, Senzo aims to make a substantial positive impact on the field of healthcare and contribute towards more effective disease management and treatment.
Click here for a full list of 6,481+ startup investors in the UK